nodes	percent_of_prediction	percent_of_DWPC	metapath
Sildenafil—PDE5A—Pentoxifylline—systemic scleroderma	0.343	0.479	CbGbCtD
Sildenafil—ADORA2A—Pentoxifylline—systemic scleroderma	0.219	0.306	CbGbCtD
Sildenafil—ABCC10—Methotrexate—systemic scleroderma	0.0518	0.0723	CbGbCtD
Sildenafil—ABCC4—Methotrexate—systemic scleroderma	0.0249	0.0347	CbGbCtD
Sildenafil—CYP2C9—Leflunomide—systemic scleroderma	0.0201	0.028	CbGbCtD
Sildenafil—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0185	0.0258	CbGbCtD
Sildenafil—CYP2D6—Captopril—systemic scleroderma	0.0144	0.0201	CbGbCtD
Sildenafil—CYP2C19—Prednisone—systemic scleroderma	0.0119	0.0166	CbGbCtD
Sildenafil—CYP2C9—cardial valve—systemic scleroderma	0.00917	0.207	CbGeAlD
Sildenafil—PDE5A—pulmonary artery—systemic scleroderma	0.00908	0.205	CbGeAlD
Sildenafil—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00721	0.0101	CbGbCtD
Sildenafil—CYP3A4—Prednisone—systemic scleroderma	0.00576	0.00804	CbGbCtD
Sildenafil—PDE5A—artery—systemic scleroderma	0.00337	0.0759	CbGeAlD
Sildenafil—PDE5A—endothelium—systemic scleroderma	0.00284	0.0641	CbGeAlD
Sildenafil—PDE5A—blood vessel—systemic scleroderma	0.00262	0.0591	CbGeAlD
Sildenafil—PDE6G—lung—systemic scleroderma	0.00205	0.0463	CbGeAlD
Sildenafil—PDE5A—connective tissue—systemic scleroderma	0.00134	0.0303	CbGeAlD
Sildenafil—PDE5A—smooth muscle tissue—systemic scleroderma	0.00123	0.0277	CbGeAlD
Sildenafil—PDE5A—digestive system—systemic scleroderma	0.000971	0.0219	CbGeAlD
Sildenafil—PDE5A—tendon—systemic scleroderma	0.000924	0.0208	CbGeAlD
Sildenafil—ABCC5—tendon—systemic scleroderma	0.000845	0.0191	CbGeAlD
Sildenafil—PDE5A—lung—systemic scleroderma	0.000811	0.0183	CbGeAlD
Sildenafil—ABCC10—digestive system—systemic scleroderma	0.000742	0.0167	CbGeAlD
Sildenafil—ABCC5—lung—systemic scleroderma	0.000742	0.0167	CbGeAlD
Sildenafil—ABCC10—tendon—systemic scleroderma	0.000706	0.0159	CbGeAlD
Sildenafil—ABCC10—lung—systemic scleroderma	0.00062	0.014	CbGeAlD
Sildenafil—ABCC4—digestive system—systemic scleroderma	0.000616	0.0139	CbGeAlD
Sildenafil—ABCC4—tendon—systemic scleroderma	0.000586	0.0132	CbGeAlD
Sildenafil—CYP1A1—skin of body—systemic scleroderma	0.000516	0.0116	CbGeAlD
Sildenafil—ABCC4—lung—systemic scleroderma	0.000514	0.0116	CbGeAlD
Sildenafil—CYP2C19—digestive system—systemic scleroderma	0.000512	0.0115	CbGeAlD
Sildenafil—CYP1A1—digestive system—systemic scleroderma	0.000413	0.0093	CbGeAlD
Sildenafil—CYP3A5—digestive system—systemic scleroderma	0.000404	0.00909	CbGeAlD
Sildenafil—CYP2C9—digestive system—systemic scleroderma	0.000397	0.00895	CbGeAlD
Sildenafil—CYP2E1—digestive system—systemic scleroderma	0.000376	0.00848	CbGeAlD
Sildenafil—CYP2E1—tendon—systemic scleroderma	0.000358	0.00807	CbGeAlD
Sildenafil—CYP1A1—lung—systemic scleroderma	0.000345	0.00777	CbGeAlD
Sildenafil—CYP3A5—lung—systemic scleroderma	0.000337	0.0076	CbGeAlD
Sildenafil—CYP2E1—lung—systemic scleroderma	0.000314	0.00708	CbGeAlD
Sildenafil—CYP3A4—digestive system—systemic scleroderma	0.000303	0.00682	CbGeAlD
Sildenafil—CYP2D6—digestive system—systemic scleroderma	0.000298	0.00672	CbGeAlD
Sildenafil—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000104	0.000433	CcSEcCtD
Sildenafil—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000432	CcSEcCtD
Sildenafil—Depression—Prednisone—systemic scleroderma	0.000103	0.000432	CcSEcCtD
Sildenafil—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000431	CcSEcCtD
Sildenafil—Urticaria—Leflunomide—systemic scleroderma	0.000103	0.00043	CcSEcCtD
Sildenafil—Abdominal pain—Leflunomide—systemic scleroderma	0.000102	0.000428	CcSEcCtD
Sildenafil—Body temperature increased—Leflunomide—systemic scleroderma	0.000102	0.000428	CcSEcCtD
Sildenafil—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000102	0.000427	CcSEcCtD
Sildenafil—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000102	0.000425	CcSEcCtD
Sildenafil—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000425	CcSEcCtD
Sildenafil—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000425	CcSEcCtD
Sildenafil—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000425	CcSEcCtD
Sildenafil—Myocardial infarction—Prednisone—systemic scleroderma	0.000101	0.000424	CcSEcCtD
Sildenafil—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000101	0.000424	CcSEcCtD
Sildenafil—Breast disorder—Methotrexate—systemic scleroderma	0.000101	0.000424	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000101	0.000424	CcSEcCtD
Sildenafil—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000423	CcSEcCtD
Sildenafil—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000101	0.000423	CcSEcCtD
Sildenafil—Hypersensitivity—Azathioprine—systemic scleroderma	0.000101	0.000422	CcSEcCtD
Sildenafil—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000101	0.000422	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000422	CcSEcCtD
Sildenafil—Insomnia—Lisinopril—systemic scleroderma	0.000101	0.00042	CcSEcCtD
Sildenafil—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.0001	0.00042	CcSEcCtD
Sildenafil—Paraesthesia—Lisinopril—systemic scleroderma	9.98e-05	0.000417	CcSEcCtD
Sildenafil—Vomiting—Captopril—systemic scleroderma	9.98e-05	0.000417	CcSEcCtD
Sildenafil—Dry mouth—Mycophenolate mofetil—systemic scleroderma	9.94e-05	0.000416	CcSEcCtD
Sildenafil—Dyspnoea—Lisinopril—systemic scleroderma	9.91e-05	0.000414	CcSEcCtD
Sildenafil—Rash—Captopril—systemic scleroderma	9.9e-05	0.000414	CcSEcCtD
Sildenafil—Dermatitis—Captopril—systemic scleroderma	9.89e-05	0.000413	CcSEcCtD
Sildenafil—Somnolence—Lisinopril—systemic scleroderma	9.88e-05	0.000413	CcSEcCtD
Sildenafil—Headache—Captopril—systemic scleroderma	9.83e-05	0.000411	CcSEcCtD
Sildenafil—Dyspepsia—Lisinopril—systemic scleroderma	9.78e-05	0.000409	CcSEcCtD
Sildenafil—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.76e-05	0.000408	CcSEcCtD
Sildenafil—Body temperature increased—Mycophenolic acid—systemic scleroderma	9.76e-05	0.000408	CcSEcCtD
Sildenafil—Oedema—Mycophenolate mofetil—systemic scleroderma	9.74e-05	0.000407	CcSEcCtD
Sildenafil—Asthma—Methotrexate—systemic scleroderma	9.7e-05	0.000406	CcSEcCtD
Sildenafil—Infection—Mycophenolate mofetil—systemic scleroderma	9.68e-05	0.000405	CcSEcCtD
Sildenafil—Decreased appetite—Lisinopril—systemic scleroderma	9.66e-05	0.000404	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Lisinopril—systemic scleroderma	9.6e-05	0.000401	CcSEcCtD
Sildenafil—Fatigue—Lisinopril—systemic scleroderma	9.58e-05	0.000401	CcSEcCtD
Sildenafil—Shock—Mycophenolate mofetil—systemic scleroderma	9.58e-05	0.000401	CcSEcCtD
Sildenafil—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	9.55e-05	0.000399	CcSEcCtD
Sildenafil—Hypersensitivity—Leflunomide—systemic scleroderma	9.53e-05	0.000399	CcSEcCtD
Sildenafil—Pain—Lisinopril—systemic scleroderma	9.51e-05	0.000398	CcSEcCtD
Sildenafil—Constipation—Lisinopril—systemic scleroderma	9.51e-05	0.000398	CcSEcCtD
Sildenafil—Tachycardia—Mycophenolate mofetil—systemic scleroderma	9.5e-05	0.000398	CcSEcCtD
Sildenafil—Skin disorder—Mycophenolate mofetil—systemic scleroderma	9.46e-05	0.000396	CcSEcCtD
Sildenafil—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	9.41e-05	0.000394	CcSEcCtD
Sildenafil—Diarrhoea—Azathioprine—systemic scleroderma	9.37e-05	0.000392	CcSEcCtD
Sildenafil—Haemoglobin—Prednisone—systemic scleroderma	9.34e-05	0.000391	CcSEcCtD
Sildenafil—Nausea—Captopril—systemic scleroderma	9.32e-05	0.00039	CcSEcCtD
Sildenafil—Haemorrhage—Prednisone—systemic scleroderma	9.29e-05	0.000389	CcSEcCtD
Sildenafil—Anorexia—Mycophenolate mofetil—systemic scleroderma	9.28e-05	0.000388	CcSEcCtD
Sildenafil—Asthenia—Leflunomide—systemic scleroderma	9.28e-05	0.000388	CcSEcCtD
Sildenafil—Feeling abnormal—Lisinopril—systemic scleroderma	9.16e-05	0.000383	CcSEcCtD
Sildenafil—Pruritus—Leflunomide—systemic scleroderma	9.15e-05	0.000383	CcSEcCtD
Sildenafil—Connective tissue disorder—Prednisone—systemic scleroderma	9.13e-05	0.000382	CcSEcCtD
Sildenafil—Hypotension—Mycophenolate mofetil—systemic scleroderma	9.1e-05	0.000381	CcSEcCtD
Sildenafil—Gastrointestinal pain—Lisinopril—systemic scleroderma	9.09e-05	0.00038	CcSEcCtD
Sildenafil—Dizziness—Azathioprine—systemic scleroderma	9.06e-05	0.000379	CcSEcCtD
Sildenafil—Upper respiratory tract infection—Methotrexate—systemic scleroderma	9.02e-05	0.000377	CcSEcCtD
Sildenafil—Erectile dysfunction—Methotrexate—systemic scleroderma	8.94e-05	0.000374	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8.87e-05	0.000371	CcSEcCtD
Sildenafil—Photosensitivity reaction—Methotrexate—systemic scleroderma	8.86e-05	0.00037	CcSEcCtD
Sildenafil—Asthenia—Mycophenolic acid—systemic scleroderma	8.85e-05	0.00037	CcSEcCtD
Sildenafil—Diarrhoea—Leflunomide—systemic scleroderma	8.85e-05	0.00037	CcSEcCtD
Sildenafil—Urticaria—Lisinopril—systemic scleroderma	8.83e-05	0.000369	CcSEcCtD
Sildenafil—Insomnia—Mycophenolate mofetil—systemic scleroderma	8.81e-05	0.000368	CcSEcCtD
Sildenafil—Abdominal pain—Lisinopril—systemic scleroderma	8.79e-05	0.000367	CcSEcCtD
Sildenafil—Body temperature increased—Lisinopril—systemic scleroderma	8.79e-05	0.000367	CcSEcCtD
Sildenafil—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	8.74e-05	0.000366	CcSEcCtD
Sildenafil—Pruritus—Mycophenolic acid—systemic scleroderma	8.73e-05	0.000365	CcSEcCtD
Sildenafil—Vomiting—Azathioprine—systemic scleroderma	8.71e-05	0.000364	CcSEcCtD
Sildenafil—Pneumonia—Methotrexate—systemic scleroderma	8.7e-05	0.000364	CcSEcCtD
Sildenafil—Eye disorder—Prednisone—systemic scleroderma	8.68e-05	0.000363	CcSEcCtD
Sildenafil—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	8.68e-05	0.000363	CcSEcCtD
Sildenafil—Somnolence—Mycophenolate mofetil—systemic scleroderma	8.66e-05	0.000362	CcSEcCtD
Sildenafil—Infestation—Methotrexate—systemic scleroderma	8.65e-05	0.000362	CcSEcCtD
Sildenafil—Infestation NOS—Methotrexate—systemic scleroderma	8.65e-05	0.000362	CcSEcCtD
Sildenafil—Rash—Azathioprine—systemic scleroderma	8.64e-05	0.000361	CcSEcCtD
Sildenafil—Dermatitis—Azathioprine—systemic scleroderma	8.63e-05	0.000361	CcSEcCtD
Sildenafil—Depression—Methotrexate—systemic scleroderma	8.63e-05	0.000361	CcSEcCtD
Sildenafil—Flushing—Prednisone—systemic scleroderma	8.62e-05	0.000361	CcSEcCtD
Sildenafil—Headache—Azathioprine—systemic scleroderma	8.58e-05	0.000359	CcSEcCtD
Sildenafil—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	8.58e-05	0.000359	CcSEcCtD
Sildenafil—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	8.57e-05	0.000359	CcSEcCtD
Sildenafil—Dizziness—Leflunomide—systemic scleroderma	8.55e-05	0.000358	CcSEcCtD
Sildenafil—Renal failure—Methotrexate—systemic scleroderma	8.5e-05	0.000356	CcSEcCtD
Sildenafil—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	8.47e-05	0.000354	CcSEcCtD
Sildenafil—Diarrhoea—Mycophenolic acid—systemic scleroderma	8.44e-05	0.000353	CcSEcCtD
Sildenafil—Stomatitis—Methotrexate—systemic scleroderma	8.43e-05	0.000353	CcSEcCtD
Sildenafil—Angiopathy—Prednisone—systemic scleroderma	8.43e-05	0.000353	CcSEcCtD
Sildenafil—Conjunctivitis—Methotrexate—systemic scleroderma	8.41e-05	0.000352	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	8.41e-05	0.000352	CcSEcCtD
Sildenafil—Immune system disorder—Prednisone—systemic scleroderma	8.39e-05	0.000351	CcSEcCtD
Sildenafil—Pain—Mycophenolate mofetil—systemic scleroderma	8.33e-05	0.000348	CcSEcCtD
Sildenafil—Constipation—Mycophenolate mofetil—systemic scleroderma	8.33e-05	0.000348	CcSEcCtD
Sildenafil—Arrhythmia—Prednisone—systemic scleroderma	8.3e-05	0.000347	CcSEcCtD
Sildenafil—Sweating—Methotrexate—systemic scleroderma	8.29e-05	0.000347	CcSEcCtD
Sildenafil—Haematuria—Methotrexate—systemic scleroderma	8.25e-05	0.000345	CcSEcCtD
Sildenafil—Vomiting—Leflunomide—systemic scleroderma	8.22e-05	0.000344	CcSEcCtD
Sildenafil—Alopecia—Prednisone—systemic scleroderma	8.21e-05	0.000343	CcSEcCtD
Sildenafil—Hypersensitivity—Lisinopril—systemic scleroderma	8.19e-05	0.000342	CcSEcCtD
Sildenafil—Dizziness—Mycophenolic acid—systemic scleroderma	8.16e-05	0.000341	CcSEcCtD
Sildenafil—Epistaxis—Methotrexate—systemic scleroderma	8.16e-05	0.000341	CcSEcCtD
Sildenafil—Rash—Leflunomide—systemic scleroderma	8.16e-05	0.000341	CcSEcCtD
Sildenafil—Dermatitis—Leflunomide—systemic scleroderma	8.15e-05	0.000341	CcSEcCtD
Sildenafil—Mental disorder—Prednisone—systemic scleroderma	8.14e-05	0.00034	CcSEcCtD
Sildenafil—Nausea—Azathioprine—systemic scleroderma	8.14e-05	0.00034	CcSEcCtD
Sildenafil—Headache—Leflunomide—systemic scleroderma	8.1e-05	0.000339	CcSEcCtD
Sildenafil—Malnutrition—Prednisone—systemic scleroderma	8.09e-05	0.000338	CcSEcCtD
Sildenafil—Erythema—Prednisone—systemic scleroderma	8.09e-05	0.000338	CcSEcCtD
Sildenafil—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	8.03e-05	0.000336	CcSEcCtD
Sildenafil—Asthenia—Lisinopril—systemic scleroderma	7.97e-05	0.000334	CcSEcCtD
Sildenafil—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.96e-05	0.000333	CcSEcCtD
Sildenafil—Pruritus—Lisinopril—systemic scleroderma	7.86e-05	0.000329	CcSEcCtD
Sildenafil—Vomiting—Mycophenolic acid—systemic scleroderma	7.85e-05	0.000328	CcSEcCtD
Sildenafil—Haemoglobin—Methotrexate—systemic scleroderma	7.8e-05	0.000326	CcSEcCtD
Sildenafil—Rash—Mycophenolic acid—systemic scleroderma	7.78e-05	0.000325	CcSEcCtD
Sildenafil—Dermatitis—Mycophenolic acid—systemic scleroderma	7.77e-05	0.000325	CcSEcCtD
Sildenafil—Haemorrhage—Methotrexate—systemic scleroderma	7.77e-05	0.000325	CcSEcCtD
Sildenafil—Urticaria—Mycophenolate mofetil—systemic scleroderma	7.74e-05	0.000324	CcSEcCtD
Sildenafil—Headache—Mycophenolic acid—systemic scleroderma	7.73e-05	0.000323	CcSEcCtD
Sildenafil—Pharyngitis—Methotrexate—systemic scleroderma	7.71e-05	0.000322	CcSEcCtD
Sildenafil—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.7e-05	0.000322	CcSEcCtD
Sildenafil—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	7.7e-05	0.000322	CcSEcCtD
Sildenafil—Nausea—Leflunomide—systemic scleroderma	7.68e-05	0.000321	CcSEcCtD
Sildenafil—Urinary tract disorder—Methotrexate—systemic scleroderma	7.67e-05	0.000321	CcSEcCtD
Sildenafil—Vision blurred—Prednisone—systemic scleroderma	7.62e-05	0.000319	CcSEcCtD
Sildenafil—Urethral disorder—Methotrexate—systemic scleroderma	7.61e-05	0.000318	CcSEcCtD
Sildenafil—Diarrhoea—Lisinopril—systemic scleroderma	7.61e-05	0.000318	CcSEcCtD
Sildenafil—Ill-defined disorder—Prednisone—systemic scleroderma	7.5e-05	0.000314	CcSEcCtD
Sildenafil—Visual impairment—Methotrexate—systemic scleroderma	7.48e-05	0.000313	CcSEcCtD
Sildenafil—Anaemia—Prednisone—systemic scleroderma	7.48e-05	0.000313	CcSEcCtD
Sildenafil—Agitation—Prednisone—systemic scleroderma	7.43e-05	0.000311	CcSEcCtD
Sildenafil—Dizziness—Lisinopril—systemic scleroderma	7.35e-05	0.000307	CcSEcCtD
Sildenafil—Erythema multiforme—Methotrexate—systemic scleroderma	7.34e-05	0.000307	CcSEcCtD
Sildenafil—Nausea—Mycophenolic acid—systemic scleroderma	7.33e-05	0.000307	CcSEcCtD
Sildenafil—Malaise—Prednisone—systemic scleroderma	7.29e-05	0.000305	CcSEcCtD
Sildenafil—Vertigo—Prednisone—systemic scleroderma	7.27e-05	0.000304	CcSEcCtD
Sildenafil—Eye disorder—Methotrexate—systemic scleroderma	7.26e-05	0.000304	CcSEcCtD
Sildenafil—Syncope—Prednisone—systemic scleroderma	7.25e-05	0.000303	CcSEcCtD
Sildenafil—Tinnitus—Methotrexate—systemic scleroderma	7.24e-05	0.000303	CcSEcCtD
Sildenafil—Cardiac disorder—Methotrexate—systemic scleroderma	7.21e-05	0.000301	CcSEcCtD
Sildenafil—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.0003	CcSEcCtD
Sildenafil—Loss of consciousness—Prednisone—systemic scleroderma	7.11e-05	0.000297	CcSEcCtD
Sildenafil—Vomiting—Lisinopril—systemic scleroderma	7.07e-05	0.000296	CcSEcCtD
Sildenafil—Angiopathy—Methotrexate—systemic scleroderma	7.05e-05	0.000295	CcSEcCtD
Sildenafil—Immune system disorder—Methotrexate—systemic scleroderma	7.01e-05	0.000293	CcSEcCtD
Sildenafil—Rash—Lisinopril—systemic scleroderma	7.01e-05	0.000293	CcSEcCtD
Sildenafil—Convulsion—Prednisone—systemic scleroderma	7.01e-05	0.000293	CcSEcCtD
Sildenafil—Dermatitis—Lisinopril—systemic scleroderma	7e-05	0.000293	CcSEcCtD
Sildenafil—Mediastinal disorder—Methotrexate—systemic scleroderma	7e-05	0.000293	CcSEcCtD
Sildenafil—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.99e-05	0.000292	CcSEcCtD
Sildenafil—Hypertension—Prednisone—systemic scleroderma	6.98e-05	0.000292	CcSEcCtD
Sildenafil—Chills—Methotrexate—systemic scleroderma	6.97e-05	0.000291	CcSEcCtD
Sildenafil—Headache—Lisinopril—systemic scleroderma	6.96e-05	0.000291	CcSEcCtD
Sildenafil—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.89e-05	0.000288	CcSEcCtD
Sildenafil—Arthralgia—Prednisone—systemic scleroderma	6.89e-05	0.000288	CcSEcCtD
Sildenafil—Myalgia—Prednisone—systemic scleroderma	6.89e-05	0.000288	CcSEcCtD
Sildenafil—Anxiety—Prednisone—systemic scleroderma	6.86e-05	0.000287	CcSEcCtD
Sildenafil—Alopecia—Methotrexate—systemic scleroderma	6.86e-05	0.000287	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	6.84e-05	0.000286	CcSEcCtD
Sildenafil—Discomfort—Prednisone—systemic scleroderma	6.8e-05	0.000285	CcSEcCtD
Sildenafil—Mental disorder—Methotrexate—systemic scleroderma	6.8e-05	0.000285	CcSEcCtD
Sildenafil—Malnutrition—Methotrexate—systemic scleroderma	6.76e-05	0.000283	CcSEcCtD
Sildenafil—Erythema—Methotrexate—systemic scleroderma	6.76e-05	0.000283	CcSEcCtD
Sildenafil—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.66e-05	0.000279	CcSEcCtD
Sildenafil—Nausea—Lisinopril—systemic scleroderma	6.6e-05	0.000276	CcSEcCtD
Sildenafil—Oedema—Prednisone—systemic scleroderma	6.6e-05	0.000276	CcSEcCtD
Sildenafil—Infection—Prednisone—systemic scleroderma	6.56e-05	0.000274	CcSEcCtD
Sildenafil—Back pain—Methotrexate—systemic scleroderma	6.54e-05	0.000273	CcSEcCtD
Sildenafil—Shock—Prednisone—systemic scleroderma	6.49e-05	0.000272	CcSEcCtD
Sildenafil—Nervous system disorder—Prednisone—systemic scleroderma	6.47e-05	0.000271	CcSEcCtD
Sildenafil—Tachycardia—Prednisone—systemic scleroderma	6.44e-05	0.000269	CcSEcCtD
Sildenafil—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.44e-05	0.000269	CcSEcCtD
Sildenafil—Skin disorder—Prednisone—systemic scleroderma	6.41e-05	0.000268	CcSEcCtD
Sildenafil—Hyperhidrosis—Prednisone—systemic scleroderma	6.38e-05	0.000267	CcSEcCtD
Sildenafil—Vision blurred—Methotrexate—systemic scleroderma	6.37e-05	0.000266	CcSEcCtD
Sildenafil—Anorexia—Prednisone—systemic scleroderma	6.29e-05	0.000263	CcSEcCtD
Sildenafil—Ill-defined disorder—Methotrexate—systemic scleroderma	6.27e-05	0.000262	CcSEcCtD
Sildenafil—Anaemia—Methotrexate—systemic scleroderma	6.25e-05	0.000261	CcSEcCtD
Sildenafil—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.000259	CcSEcCtD
Sildenafil—Rash—Mycophenolate mofetil—systemic scleroderma	6.14e-05	0.000257	CcSEcCtD
Sildenafil—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.13e-05	0.000257	CcSEcCtD
Sildenafil—Headache—Mycophenolate mofetil—systemic scleroderma	6.1e-05	0.000255	CcSEcCtD
Sildenafil—Malaise—Methotrexate—systemic scleroderma	6.1e-05	0.000255	CcSEcCtD
Sildenafil—Vertigo—Methotrexate—systemic scleroderma	6.07e-05	0.000254	CcSEcCtD
Sildenafil—Leukopenia—Methotrexate—systemic scleroderma	6.05e-05	0.000253	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Prednisone—systemic scleroderma	6.01e-05	0.000252	CcSEcCtD
Sildenafil—Insomnia—Prednisone—systemic scleroderma	5.97e-05	0.00025	CcSEcCtD
Sildenafil—Paraesthesia—Prednisone—systemic scleroderma	5.93e-05	0.000248	CcSEcCtD
Sildenafil—Cough—Methotrexate—systemic scleroderma	5.9e-05	0.000247	CcSEcCtD
Sildenafil—Convulsion—Methotrexate—systemic scleroderma	5.86e-05	0.000245	CcSEcCtD
Sildenafil—Dyspepsia—Prednisone—systemic scleroderma	5.81e-05	0.000243	CcSEcCtD
Sildenafil—Nausea—Mycophenolate mofetil—systemic scleroderma	5.78e-05	0.000242	CcSEcCtD
Sildenafil—Myalgia—Methotrexate—systemic scleroderma	5.76e-05	0.000241	CcSEcCtD
Sildenafil—Chest pain—Methotrexate—systemic scleroderma	5.76e-05	0.000241	CcSEcCtD
Sildenafil—Arthralgia—Methotrexate—systemic scleroderma	5.76e-05	0.000241	CcSEcCtD
Sildenafil—Decreased appetite—Prednisone—systemic scleroderma	5.74e-05	0.00024	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.72e-05	0.000239	CcSEcCtD
Sildenafil—Fatigue—Prednisone—systemic scleroderma	5.69e-05	0.000238	CcSEcCtD
Sildenafil—Discomfort—Methotrexate—systemic scleroderma	5.69e-05	0.000238	CcSEcCtD
Sildenafil—Constipation—Prednisone—systemic scleroderma	5.65e-05	0.000236	CcSEcCtD
Sildenafil—Infection—Methotrexate—systemic scleroderma	5.48e-05	0.000229	CcSEcCtD
Sildenafil—Feeling abnormal—Prednisone—systemic scleroderma	5.44e-05	0.000228	CcSEcCtD
Sildenafil—Nervous system disorder—Methotrexate—systemic scleroderma	5.41e-05	0.000226	CcSEcCtD
Sildenafil—Gastrointestinal pain—Prednisone—systemic scleroderma	5.4e-05	0.000226	CcSEcCtD
Sildenafil—Skin disorder—Methotrexate—systemic scleroderma	5.36e-05	0.000224	CcSEcCtD
Sildenafil—Hyperhidrosis—Methotrexate—systemic scleroderma	5.33e-05	0.000223	CcSEcCtD
Sildenafil—Anorexia—Methotrexate—systemic scleroderma	5.26e-05	0.00022	CcSEcCtD
Sildenafil—Urticaria—Prednisone—systemic scleroderma	5.24e-05	0.000219	CcSEcCtD
Sildenafil—Abdominal pain—Prednisone—systemic scleroderma	5.22e-05	0.000218	CcSEcCtD
Sildenafil—Body temperature increased—Prednisone—systemic scleroderma	5.22e-05	0.000218	CcSEcCtD
Sildenafil—Hypotension—Methotrexate—systemic scleroderma	5.16e-05	0.000216	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.03e-05	0.00021	CcSEcCtD
Sildenafil—Insomnia—Methotrexate—systemic scleroderma	4.99e-05	0.000209	CcSEcCtD
Sildenafil—Paraesthesia—Methotrexate—systemic scleroderma	4.95e-05	0.000207	CcSEcCtD
Sildenafil—Dyspnoea—Methotrexate—systemic scleroderma	4.92e-05	0.000206	CcSEcCtD
Sildenafil—Somnolence—Methotrexate—systemic scleroderma	4.9e-05	0.000205	CcSEcCtD
Sildenafil—Hypersensitivity—Prednisone—systemic scleroderma	4.86e-05	0.000203	CcSEcCtD
Sildenafil—Dyspepsia—Methotrexate—systemic scleroderma	4.86e-05	0.000203	CcSEcCtD
Sildenafil—Decreased appetite—Methotrexate—systemic scleroderma	4.8e-05	0.000201	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.76e-05	0.000199	CcSEcCtD
Sildenafil—Fatigue—Methotrexate—systemic scleroderma	4.76e-05	0.000199	CcSEcCtD
Sildenafil—Asthenia—Prednisone—systemic scleroderma	4.74e-05	0.000198	CcSEcCtD
Sildenafil—Pain—Methotrexate—systemic scleroderma	4.72e-05	0.000197	CcSEcCtD
Sildenafil—Pruritus—Prednisone—systemic scleroderma	4.67e-05	0.000195	CcSEcCtD
Sildenafil—Feeling abnormal—Methotrexate—systemic scleroderma	4.55e-05	0.00019	CcSEcCtD
Sildenafil—Diarrhoea—Prednisone—systemic scleroderma	4.52e-05	0.000189	CcSEcCtD
Sildenafil—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.51e-05	0.000189	CcSEcCtD
Sildenafil—Urticaria—Methotrexate—systemic scleroderma	4.38e-05	0.000183	CcSEcCtD
Sildenafil—Dizziness—Prednisone—systemic scleroderma	4.37e-05	0.000183	CcSEcCtD
Sildenafil—Body temperature increased—Methotrexate—systemic scleroderma	4.36e-05	0.000182	CcSEcCtD
Sildenafil—Abdominal pain—Methotrexate—systemic scleroderma	4.36e-05	0.000182	CcSEcCtD
Sildenafil—Vomiting—Prednisone—systemic scleroderma	4.2e-05	0.000176	CcSEcCtD
Sildenafil—Rash—Prednisone—systemic scleroderma	4.16e-05	0.000174	CcSEcCtD
Sildenafil—Dermatitis—Prednisone—systemic scleroderma	4.16e-05	0.000174	CcSEcCtD
Sildenafil—Headache—Prednisone—systemic scleroderma	4.14e-05	0.000173	CcSEcCtD
Sildenafil—Hypersensitivity—Methotrexate—systemic scleroderma	4.06e-05	0.00017	CcSEcCtD
Sildenafil—Asthenia—Methotrexate—systemic scleroderma	3.96e-05	0.000166	CcSEcCtD
Sildenafil—Nausea—Prednisone—systemic scleroderma	3.92e-05	0.000164	CcSEcCtD
Sildenafil—Pruritus—Methotrexate—systemic scleroderma	3.9e-05	0.000163	CcSEcCtD
Sildenafil—Diarrhoea—Methotrexate—systemic scleroderma	3.77e-05	0.000158	CcSEcCtD
Sildenafil—Dizziness—Methotrexate—systemic scleroderma	3.65e-05	0.000153	CcSEcCtD
Sildenafil—Vomiting—Methotrexate—systemic scleroderma	3.51e-05	0.000147	CcSEcCtD
Sildenafil—Rash—Methotrexate—systemic scleroderma	3.48e-05	0.000145	CcSEcCtD
Sildenafil—Dermatitis—Methotrexate—systemic scleroderma	3.48e-05	0.000145	CcSEcCtD
Sildenafil—Headache—Methotrexate—systemic scleroderma	3.46e-05	0.000145	CcSEcCtD
Sildenafil—Nausea—Methotrexate—systemic scleroderma	3.28e-05	0.000137	CcSEcCtD
